Innovative Diagnostic Technologies Diazyme's proprietary enzyme technologies enable the development of versatile diagnostic reagents compatible with most automated chemistry analyzers, creating opportunities to expand product offerings across various clinical testing markets such as cardiovascular, liver, and cancer markers.

Recent Product Launches The company's recent introduction of enhanced colorimetric assays and sample preparation demonstration videos demonstrate ongoing innovation and a focus on improving laboratory workflows, positioning them to attract laboratory equipment and reagent procurement opportunities.

Regulatory Approvals With FDA EUA approvals for critical diagnostic tests like the SARS-CoV-2 RT-PCR and FDA 510(k) exemptions, Diazyme is well-positioned to leverage these regulatory milestones to expand into infectious disease testing and secure government or institutional contracts.

Strategic Collaborations Partnerships with major industry players such as Maccura Biotechnology and Ortho Clinical Diagnostics provide leverage for joint product development and distribution channels, opening doors for co-marketing and bundled offerings to healthcare providers and labs.

Market Focus and Certifications Being located in a regulated environment with cGMP and ISO 13485 certifications, combined with a focus on diagnostic reagents for automated analyzers, allows Diazyme to confidently pursue large hospital laboratories, diagnostic centers, and supply chain integrations for expanding market share.